Pharmacists and Pharmacy Technicians

1. Examine the documentation requirements for the compounding and dispensing process of ketamine, in accordance with regulatory standards and best practices, to foster comprehension of accountability and traceability principles.
2. Review the legal obligations of pharmacists regarding controlled substances, including DEA and state regulations, and their implications for dispensing practices.
3. Recognize the importance of implementing effective strategies for identifying signs of misuse or diversion through the utilization of the Prescription Drug Monitoring Programs (PDMPs) and thorough patient and prescriber verification processes. 
4. Recall FDA guidance on when a pharmacy can compound a drug that is "essentially a copy" of a FDA approved drug product, focusing on its implications for compounding of GLP-1 drugs listed on the FDA drug shortage list.
5. Assess the considerations and challenges associated with compounding GLP-1 drugs listed on the FDA drug shortage list, including formulation adjustments, sourcing of ingredients, and maintaining quality assurance measures.